Article ; Online: Experience of Subcutaneous Levetiracetam in Palliative Care.
2023 Volume 32, Issue 1, Page(s) 90–95
Abstract: Background: Seizures are common in palliative care patients and its control is essential in the management of these patients as it helps to reduce suffering at the end of life. Subcutaneous levetiracetam has been used off-license for seizure control in ... ...
| Abstract | Background: Seizures are common in palliative care patients and its control is essential in the management of these patients as it helps to reduce suffering at the end of life. Subcutaneous levetiracetam has been used off-license for seizure control in palliative care. Objective: The objective of the study was to describe our experience with subcutaneous levetiracetam in two hospitals in Bogota, Colombia. Methods: We conducted a retrospective review of patients treated with subcutaneous levetiracetam in two hospitals in Colombia during 2019-2021. Data were extracted from medical records, and participants were followed up as outpatients. Results: Twenty-one patients were included into the study. No severe adverse effects or rise in ictal frequency were documented. Twelve patients died during hospitalization and nine continued treatments as outpatients. The principal diagnosis was structural focal epilepsy. The daily dose of levetiracetam ranged from 1,000 mg to 3,000 mg, and the duration of treatment varied among subjects between 1 and 360 days. Conclusion: Subcutaneous levetiracetam was well tolerated and effective in controlling seizures in palliative care when oral administration or intravenous access was not an option. Randomized controlled trials are needed to elucidate the efficacy and tolerability of subcutaneous levetiracetam in clinical practice. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Humans ; Levetiracetam/therapeutic use ; Anticonvulsants/therapeutic use ; Anticonvulsants/adverse effects ; Palliative Care ; Piracetam/therapeutic use ; Piracetam/adverse effects ; Seizures/drug therapy ; Treatment Outcome | |||||
| Chemical Substances | Levetiracetam (44YRR34555) ; Anticonvulsants ; Piracetam (ZH516LNZ10) | |||||
| Language | English | |||||
| Publishing date | 2023-02-02 | |||||
| Publishing country | Switzerland | |||||
| Document type | News | |||||
| ZDB-ID | 645108-1 | |||||
| ISSN | 1423-0151 ; 1011-7571 | |||||
| ISSN (online) | 1423-0151 | |||||
| ISSN | 1011-7571 | |||||
| DOI | 10.1159/000529461 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2486: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.